{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:14:44Z","timestamp":1770959684187,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Arbutus Biopharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>HBV RNA destabilizers are a class of small-molecule compounds that target the noncanonical poly(A) RNA polymerases PAPD5 and PAPD7, resulting in HBV RNA degradation and the suppression of viral proteins including the hepatitis B surface antigen (HBsAg). AB-161 is a next-generation HBV RNA destabilizer with potent antiviral activity, inhibiting HBsAg expressed from cccDNA and integrated HBV DNA in HBV cell-based models. AB-161 exhibits broad HBV genotype coverage, maintains activity against variants resistant to nucleoside analogs, and shows additive effects on HBV replication when combined with other classes of HBV inhibitors. In AAV-HBV-transduced mice, the dose-dependent reduction of HBsAg correlated with concentrations of AB-161 in the liver reaching above its effective concentration mediating 90% inhibition (EC90), compared to concentrations in plasma which were substantially below its EC90, indicating that high liver exposure drives antiviral activities. In preclinical 13-week safety studies, minor non-adverse delays in sensory nerve conductance velocity were noted in the high-dose groups in rats and dogs. However, all nerve conduction metrics remained within physiologically normal ranges, with no neurobehavioral or histopathological findings. Despite the improved neurotoxicity profile, microscopic findings associated with male reproductive toxicity were detected in dogs, which subsequently led to the discontinuation of AB-161\u2019s clinical development.<\/jats:p>","DOI":"10.3390\/v16030323","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T04:23:10Z","timestamp":1708489390000},"page":"323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-0001","authenticated-orcid":false,"given":"Angela M.","family":"Lam","sequence":"first","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi R.","family":"Dugyala","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Sheraz","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily P.","family":"Thi","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7244-7569","authenticated-orcid":false,"given":"Ingrid E.","family":"Graves","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cuconati","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly Micolochick","family":"Steuer","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Ardzinski","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Overholt","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-0773","authenticated-orcid":false,"given":"Jeremy D.","family":"Mason","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitar","family":"Gotchev","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-2752","authenticated-orcid":false,"given":"Andrew G.","family":"Cole","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy O.","family":"Harasym","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Sofia","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, February 13). Global Hepatitis Report. Available online: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Moini, M., and Fung, S. (2022). HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses, 14.","DOI":"10.3390\/v14040657"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00535-021-01780-5","article-title":"Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy","volume":"56","author":"Mak","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: A possible immune escape mechanism of hepatitis B virus","volume":"126","author":"Binda","year":"2009","journal-title":"Immunology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Shi, B., Ren, G., Hu, Y., Wang, S., Zhang, Z., and Yuan, Z. (2012). HBsAg inhibits IFN-\u03b1 production in plasmacytoid dendritic cells through TNF-\u03b1 and IL-10 induction in monocytes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044900"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials","volume":"79","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2023.07.026","article-title":"First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection","volume":"79","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41594-020-0427-3","article-title":"Viral hijacking of the TENT4-ZCCHC14 complex protects viral RNAs via mixed tailing","volume":"27","author":"Kim","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0057421","DOI":"10.1128\/JVI.00574-21","article-title":"Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNA","volume":"95","author":"Liu","year":"2021","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.30329","article-title":"PAPD5\/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization","volume":"69","author":"Mueller","year":"2019","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Hayashi, S., Zhaoyu, Y., Inada, H., Nagaoka, K., Tateyama, M., and Tanaka, Y. (2024). A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA. J. Gastroenterol.","DOI":"10.1007\/s00535-023-02070-y"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.antiviral.2017.11.009","article-title":"HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element","volume":"149","author":"Zhou","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hu, Y., Sun, F., Yuan, Q., Du, J., Hu, L., Gu, Z., Zhou, Q., Du, X., He, S., and Sun, Y. (2022). Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. Bioorg. Med. Chem. Lett., 75.","DOI":"10.1016\/j.bmcl.2022.128977"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2017.10.014","article-title":"A novel orally available small molecule that inhibits hepatitis B virus expression","volume":"68","author":"Mueller","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/hep4.1502","article-title":"Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-\u03b1 in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus","volume":"4","author":"Menne","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0009422","DOI":"10.1128\/aac.00094-22","article-title":"Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: A First-in-Human Single- and Multiple-Dose Escalation Trial","volume":"66","author":"Li","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105407","DOI":"10.1016\/j.yrtph.2023.105407","article-title":"Unexpected neurotoxicity in chronic toxicity studies with a HBV viral expression inhibitor","volume":"141","author":"Bopst","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/toxsci\/kfac009","article-title":"Neurotoxicity of an Hepatitis B Virus (HBV) Transcript Inhibitor in 13-Week Rat and Monkey Studies","volume":"186","author":"Lake","year":"2022","journal-title":"Toxicol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/acs.jmedchem.3c01981","article-title":"Structure-Activity Relationships and Discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido [1,2-h][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer","volume":"67","author":"Gotchev","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","article-title":"Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA","volume":"84","author":"Sells","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","first-page":"3858","article-title":"Growth of human hepatoma cells lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bjc.1976.205","article-title":"Hepatitis B surface antigen produced by a human hepatoma cell line","volume":"34","author":"MacNab","year":"1976","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"Iwamoto","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antiviral Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-4608(85)90034-2","article-title":"The PLC\/PRF\/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites","volume":"18","author":"Bowcock","year":"1985","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00640-20","DOI":"10.1128\/AAC.00640-20","article-title":"The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA","volume":"65","author":"Sun","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","article-title":"Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1128\/JVI.03134-12","article-title":"Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules","volume":"87","author":"Dion","year":"2013","journal-title":"J. Virol."},{"key":"ref_37","first-page":"1511","article-title":"A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery","volume":"39","author":"Huang","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients with Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/S0168-8278(22)01999-7","article-title":"Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells","volume":"77","author":"Ganchua","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S878","DOI":"10.1016\/S0168-8278(22)02050-5","article-title":"Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_42","first-page":"S203","article-title":"Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression","volume":"75","author":"Yuen","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.yrtph.2018.04.007","article-title":"An innovative investigative approach to characterize the effects observed in a combined fertility study in male and female rats","volume":"95","author":"Xie","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:11Z","timestamp":1760104931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["v16030323"],"URL":"https:\/\/doi.org\/10.3390\/v16030323","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}